Virginia Commonwealth University

VCU Massey Cancer Center

The $125 billion question: how will the ACA affect cancer survivors?

Sabik Barnes Bradley for ACA blog post

In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”

Continue reading →

Shaping the minds of future cancer researchers

Ross B. Mikkelsen, Ph.D.

Cancer researcher Ross B. Mikkelsen, Ph.D., member of the Radiation Biology and Oncology research program at VCU Massey Cancer Center tells his students, “researchers aren’t stupid because we make stupid mistakes, but because we don’t know what’s on the other side of an experiment. On the other hand, when you do find out what’s on the other side, you get a high that you can’t beat.”

Continue reading →

Top 5 stories from 2013

Top 5 blog posts

2013 brought on some great new research from Massey. Here are the top five stories from the past year: 1. Targeted viral therapy destroys breast cancer stem cells in preclinical experiments 2. Drug combination therapy causes cancer cells to "eat themselves" 3. From head to toe: how to perform a skin self-exam 4. Researchers look to mathematics, nature...

Continue reading →

Six Massey physicians earn 2013 Best Bedside Manner recognition

Our Health Richmond Bedside Manner

In the December 2013 issue of Our Health Richmond magazine, six Massey physicians were recognized for their kindness, empathy and attentiveness when working with patients. These inaugural Best Bedside Manner Awards seek to recognize professionals who incorporate compassionate care into their practice.

Continue reading →

Scientists uncover new target for brain cancer treatment

Keggleman Fisher Das

A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme (GBM), the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease’s aggressive and invasive nature.

Continue reading →